Product Brochure

Reduced NMN Can Boost NAD+ by 10X Safety Validated

Overview

NMNH refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.

UthPeak™, EffePharm's pioneering NMNH product, received significant attention during Vitafoods Europe 2024. UthPeak™ has completed rigorous toxicology and efficacy tests, proving its safety and benefits for anti-aging, anti-fatigue, and cardiovascular health.

UthPeak™ is currently conducting a phase I clinical trial, with results expected by the end of 2024. UthPeak™ NMNH finished products are available to purchase on Amazon.

Download the file now to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”